- Aug 24, 2021TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
- Mar 16, 2021TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
- Sep 29, 2020TearClear Appoints Robert Bailey to Board of Directors
- Aug 11, 2020TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
- May 20, 2020TearClear appoints Dr. Amir Shojaei Chief Development Officer
- Apr 15, 2020TearClear appoints Robert J. Dempsey Chief Executive Officer